Osteopenia: Causes, Diagnosis, Treatment, and When to Act

What Osteopenia Actually Means

Osteopenia is not a disease. It is a bone-density category defined by the World Health Organization in 1994 as a T-score between -1.0 and -2.5, measured by DEXA at the lumbar spine or femoral neck. The T-score compares your bone mineral density (BMD) to the mean peak BMD of a healthy 30-year-old reference population of the same sex. A score of -1.5, for example, means your BMD is 1.5 standard deviations below that peak. [1]

The word "pre-osteoporosis" is sometimes used informally, but the two conditions exist on the same continuum rather than as completely separate entities. Data from the National Health and Nutrition Examination Survey (NHANES) estimated that roughly 43 million American adults aged 50 and older had low bone mass in 2010, and that number was projected to rise to 48 million by 2030. [2]

T-score alone does not determine fracture risk adequately. Two people with identical T-scores can have very different 10-year fracture probabilities depending on age, sex, prior fracture history, glucocorticoid use, rheumatoid arthritis, parental hip fracture history, smoking, alcohol intake, and body mass index. The FRAX tool, developed by the University of Sheffield with WHO backing, incorporates all of these variables. Current National Osteoporosis Foundation (NOF) guidelines recommend pharmacologic treatment when the 10-year probability of a major osteoporotic fracture reaches or exceeds 20%, or when hip fracture probability reaches or exceeds 3%, regardless of whether the T-score crosses into the osteoporosis zone. [3]

How Bone Remodeling Works and Where It Goes Wrong

Bone is living tissue undergoing constant resorption by osteoclasts and formation by osteoblasts. In healthy young adults, resorption and formation stay roughly balanced. Peak bone mass is typically reached between ages 25 and 30, after which the balance slowly tilts toward net loss at a rate of roughly 0.5 to 1% per year. [4]

Estrogen suppresses osteoclast activity. Testosterone does the same, partly through aromatization to estradiol within bone tissue. When either hormone drops sharply, osteoclast activity accelerates beyond what osteoblasts can offset.

Parathyroid hormone (PTH), calcitonin, vitamin D, and insulin-like growth factor-1 (IGF-1) also regulate this balance. Vitamin D deficiency reduces intestinal calcium absorption, forcing PTH to pull calcium out of bone to maintain serum levels. Chronic low-grade PTH elevation is one of the more correctable contributors to bone loss and one reason that correcting vitamin D status is addressed before anything else in most clinical protocols. [5]

Postmenopausal Bone Loss: Why the First Five Years Matter Most

The steepest bone loss in women occurs in the two years before and the three years immediately after the final menstrual period. During this window, women may lose 3 to 5% of BMD per year at the spine and 1 to 3% at the hip. [6] That rate then slows to roughly 1 to 2% annually and eventually approaches the background aging rate of both sexes.

The 2023 Menopause Society (formerly NAMS) position statement states directly: "Menopausal hormone therapy (MHT) is the most effective treatment for vasomotor symptoms and is also effective for the prevention of osteoporosis-related fractures in postmenopausal women." [7]

The Women's Health Initiative (WHI), which enrolled 16,608 postmenopausal women aged 50, 79, found that conjugated equine estrogen plus medroxyprogesterone acetate reduced hip fracture incidence by 34% (hazard ratio 0.66 to 95% CI 0.45, 0.98) compared with placebo after a mean follow-up of 5.2 years. [8] This fracture benefit appeared even in women who started MHT with normal or osteopenic (rather than osteoporotic) BMD, supporting early intervention.

For women who cannot or choose not to use MHT, bisphosphonates remain the standard pharmacologic option. The FIT (Fracture Intervention Trial) demonstrated that alendronate reduced vertebral fracture risk by 47% over three years in postmenopausal women with low BMD. [9] Alendronate 70 mg once weekly oral is the generic, low-cost first-line choice; weekly risedronate 35 mg is an alternative with a slightly lower rate of upper GI side effects.

Osteopenia in Men: Under-Recognized and Under-Treated

Men develop osteoporosis and osteopenia about a decade later than women, but one in four men over 50 will sustain an osteoporosis-related fracture in their lifetime. [10] After a hip fracture, men have a higher short-term mortality than women: approximately 37% die within one year, compared with about 20% in women, according to a meta-analysis published in Osteoporosis International. [11]

Male bone loss accelerates with declining testosterone, but the estradiol component is the dominant driver of skeletal maintenance in men as well. Hypogonadism (total testosterone below 300 ng/dL by most guidelines) is an independent risk factor for osteopenia and warrants DEXA screening even in men younger than 50. [12]

Other male-specific risk factors include:

• Chronic alcohol use (more than 3 units/day)
• Androgen deprivation therapy (ADT) for prostate cancer
• Chronic kidney disease stages 3b through 5
• Celiac disease or inflammatory bowel disease causing calcium malabsorption
• Long-term proton pump inhibitor use (reduces gastric acid needed for calcium solubilization)

The Endocrine Society's 2012 clinical practice guideline on male osteoporosis recommended DEXA screening in all men aged 70 and older, and in men aged 50, 69 with one or more clinical risk factors. [13] Treatment thresholds mirror those used in women: FRAX-based major fracture risk at or above 20%, or hip fracture risk at or above 3%.

Alendronate and risedronate are FDA-approved for male osteoporosis. Zoledronic acid 5 mg IV once yearly is another approved option and eliminates adherence concerns associated with weekly oral dosing. The HORIZON Key Fracture Trial showed zoledronic acid reduced morphometric vertebral fractures by 70% at three years. [14]

Steroid-Induced Osteoporosis: A Preventable Emergency

Glucocorticoids are the most common cause of secondary osteoporosis worldwide. As many as 50% of patients on long-term glucocorticoid therapy develop fractures, often at higher bone-density values than would predict fracture in the general population. [15] This happens because glucocorticoids directly suppress osteoblast function, increase osteoclast lifespan, impair intestinal calcium absorption, and raise urinary calcium excretion simultaneously.

The American College of Rheumatology (ACR) 2022 guideline on glucocorticoid-induced osteoporosis applies to any patient expected to take prednisone equivalent ≥2.5 mg/day for three months or longer. Key recommendations include [16]:

1. Begin calcium (1,000, 1 to 200 mg/day) and vitamin D (600 to 800 IU/day minimum, titrated to serum 25(OH)D above 20 ng/mL) immediately at glucocorticoid initiation.
2. Calculate FRAX with a glucocorticoid dose adjustment (the FRAX calculator has a checkbox for "ever glucocorticoid use," which underestimates risk; the ACR recommends adjusting the major fracture probability upward by 15% and hip fracture probability upward by 20% for patients on medium-to-high doses).
3. Start oral bisphosphonate therapy in any patient classified as moderate or high fracture risk. High-risk patients (prior osteoporotic fracture, T-score at or below -2.5, or FRAX major fracture ≥20% after adjustment) should receive either zoledronic acid or teriparatide (Forteo) 20 mcg subcutaneous daily rather than an oral bisphosphonate.

Bone loss on glucocorticoids is fastest in the first 6 to 12 months and predominantly trabecular, meaning the spine is affected before the hip. DEXA should be obtained within 6 months of starting long-term steroids and repeated at 1 to 2 year intervals depending on ongoing dose. [16]

The HealthRX clinical team uses a three-tier triage framework for steroid-induced osteopenia: Tier 1 (low dose <5 mg/day, short duration, low FRAX) receives calcium and vitamin D plus lifestyle counseling alone; Tier 2 (medium dose 5 to 10 mg/day or FRAX-adjusted major fracture risk 10 to 20%) receives calcium, vitamin D, and oral bisphosphonate; Tier 3 (high dose >10 mg/day, prior fragility fracture, or FRAX-adjusted major fracture risk >20%) receives IV zoledronic acid or teriparatide plus endocrinology co-management. This framework is adapted from the ACR 2022 guideline and the NOF Clinician's Guide and is reviewed annually against updated evidence.

Lifestyle and Non-Pharmacologic Strategies: Specific Targets

Exercise is not a vague recommendation. Weight-bearing and resistance exercise programs specifically designed to load the axial skeleton produce measurable BMD gains. A 2019 Cochrane review of 83 randomized trials (N=4,420) found that progressive resistance training significantly increased lumbar spine BMD (mean difference 0.89%, 95% CI 0.22, 1.56) compared with non-exercising controls over 12 to 24 months. [17]

Practical targets based on guideline synthesis:

• Resistance training: 2, 3 sessions per week, loading major muscle groups, progressing load every 4 to 6 weeks.
• Impact activity: Jumping or jogging adds ground-reaction-force stimulus to hip cortical bone; even 10, 20 jumps per day showed hip BMD improvements in early postmenopausal women in one 12-month trial.
• Calcium: Total intake (diet plus supplement) of 1 to 000 mg/day for adults 19, 50, 1 to 200 mg/day for women over 50 and men over 70. Spreading doses to 500 mg at a time improves absorption. Calcium carbonate requires stomach acid (take with food); calcium citrate does not (preferred in patients on PPIs or achlorhydria). [18]
• Vitamin D: The Endocrine Society recommends 1,500, 2 to 000 IU/day for adults at risk for deficiency, targeting serum 25(OH)D above 30 ng/mL. [5] The VITAL trial (N=25,871) did not show fracture reduction at the population level but enrolled largely vitamin D-sufficient individuals at baseline, limiting applicability to those who are deficient. [19]
• Protein: Adequate dietary protein (1.0 to 1.2 g/kg/day) supports osteoblast function and IGF-1 signaling. Protein restriction in elderly populations correlates with accelerated bone loss.
• Smoking cessation: Active smoking doubles the rate of bone loss and impairs intestinal calcium absorption. [20]
• Alcohol: Limiting intake to fewer than 2 standard drinks per day removes a dose-dependent suppressor of osteoblast activity.

Fall prevention deserves separate attention. Most osteoporotic fractures result from low-level trauma, meaning a fall rather than spontaneous fracture. Balance training (tai chi, single-leg standing), home hazard assessment, and medication review (sedatives, antihypertensives causing orthostatic hypotension) reduce fall rates by 21 to 24% in older adults. [21]

Reading Your DEXA Report: T-Score vs. Z-Score

DEXA reports contain two scores that are frequently confused.

The T-score compares BMD to peak young-adult reference data and is the diagnostic value used to classify normal, osteopenic, or osteoporotic status. It applies to postmenopausal women and men aged 50 and older.

The Z-score compares BMD to age-matched and sex-matched reference data. A Z-score at or below -2.0 in premenopausal women or men younger than 50 is described as "below the expected range for age" and should trigger evaluation for secondary causes: hyperparathyroidism, hyperthyroidism, celiac disease, vitamin D deficiency, kidney disease, or medications. [1]

DEXA at the lumbar spine (L1, L4) and total hip (femoral neck) is the standard measurement site. Forearm (radius) DEXA is added when hip and spine measurements are technically unreliable (bilateral hip replacement, severe spinal arthritis with osteophytes inflating the spine score) or in patients with hyperparathyroidism where distal cortical bone is preferentially affected.

Precision errors of DEXA are roughly 1 to 1.5% at the spine and 1.5 to 2% at the hip. A true biologically significant change between two scans requires a difference exceeding the least significant change (LSC) for that specific machine and technologist, typically 3 to 4% at the spine and 4 to 6% at the hip. Interpreting a 1% BMD change as "improvement" between scans is statistically meaningless. [1]

When to Start Medication: Applying the FRAX Threshold

The decision to prescribe a bisphosphonate in osteopenia is not automatic. An otherwise healthy 52-year-old woman with a T-score of -1.8, no prior fracture, no glucocorticoid use, no family history of hip fracture, non-smoker, BMI 24, may calculate a 10-year major fracture risk of only 8% and a hip fracture risk of 1%. Pharmacotherapy at that point adds cost, GI side effects, and theoretical long-term risk (osteonecrosis of the jaw, atypical femur fracture with very long bisphosphonate use) without a net benefit proven by trial data. [22]

Conversely, a 64-year-old man with a T-score of -2.0 who has been on prednisone 7.5 mg/day for rheumatoid arthritis for two years, smokes, has a prior wrist fracture, and whose father had a hip fracture may calculate an adjusted 10-year major fracture risk above 25%. That patient benefits from a bisphosphonate even though his T-score has not reached -2.5.

The NOF Clinician's Guide to Prevention and Treatment of Osteoporosis (2023 update) states: "Pharmacologic treatment should be considered for postmenopausal women and men age 50 and older with osteopenia who have a 10-year probability of a major osteoporosis-related fracture of 20 percent or more or a 10-year probability of hip fracture of 3 percent or more based on the U.S.-adapted FRAX." [3]

Anabolic agents (teriparatide, abaloparatide) and anti-resorptive biologics (denosumab, romosozumab) are generally reserved for patients who already have osteoporosis with fracture, very low T-scores, or who cannot tolerate bisphosphonates, given their cost, route of administration, and rebound bone loss on discontinuation. A prescriber who starts denosumab in a patient with osteopenia rather than osteoporosis must plan an exit strategy (typically transitioning to a bisphosphonate) to prevent the rapid rebound resorption that occurs when denosumab is stopped. [23]

Monitoring Response to Treatment

Bone turnover markers (BTMs) can confirm that anti-resorptive therapy is working before the next DEXA scan. Serum CTX (C-terminal telopeptide of type I collagen) reflects osteoclast activity; serum P1NP (procollagen type 1 N-terminal propeptide) reflects osteoblast activity. On a bisphosphonate, CTX should fall by at least 25 to 30% from baseline within 3 to 6 months. [24] If it does not, poor adherence, malabsorption, or vitamin D deficiency are the most common explanations.

DEXA is typically repeated at 1 to 2 year intervals while on treatment, extending to every 2 years once stability is established. After 3 to 5 years of oral bisphosphonate, a "bisphosphonate holiday" (temporary discontinuation) is appropriate for patients who entered treatment with osteopenia and whose BMD has responded well, because skeletal retention of the drug provides continued protection for 1 to 3 years after stopping. The holiday is not appropriate for patients who remain at high fracture risk. [22]